Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systems Biological Analysis of Immune Responses to RSV Vaccine
NCT07185399Phase 4Active, not recruiting
- Sponsor
- Emory University
- Start
- Oct 2025
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV), sponsored by Emory University. Primary endpoint: Antibody Titers at 365 days. Started Oct 2025; status: active, not recruiting.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07185399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185399.